Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,991JPY
17 Feb 2017
Change (% chg)

¥6 (+0.30%)
Prev Close
¥1,985
Open
¥1,967
Day's High
¥2,004
Day's Low
¥1,962
Volume
777,200
Avg. Vol
1,187,991
52-wk High
¥2,134
52-wk Low
¥1,175

Latest Key Developments (Source: Significant Developments)

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook
Thursday, 16 Jul 2015 02:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A".Rating outlook stable.  Full Article

Sumitomo Dainippon Pharma and JCR Pharmaceuticals conclude a feasibility study agreement on application of the blood-brain barrier penetration technology in psychiatry and neurology area
Wednesday, 17 Jun 2015 03:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd and JCR Pharmaceuticals Co Ltd:JCR Pharmaceuticals (“JCR”) and Sumitomo Dainippon Pharma executed on June 17 a feasibility study agreement.Under which they will study the feasibility of applying JCR’s proprietary blood-brain barrier penetration technology “J-Brain Cargo” to discovery of new treatment in the psychiatry and neurology area.Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma’s choice.With a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist.  Full Article

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Company Ltd announce decision to terminate agreement
Thursday, 7 May 2015 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Company Ltd:Says their license agreement entered into in March 2011 (agreement) will be terminated.Says companies are starting discussions in an effort to finalize and execute a mutual agreement establishing a transition plan for orderly transfer of all development and commercialization rights and activities with respect to Latuda to Sumitomo Dainippon Pharma.Says agreement entered For joint development and exclusive commercialization of pharmaceutical products containing lurasidone hydrochloride (Latuda), an atypical antipsychotic agent, in Europe.Takeda's right to develop and commercialize Latuda within 26 member states of the European Union (excluding U.K), Switzerland, Norway, Turkey and Russia, will transfer back to Sumitomo Dainippon Pharma upon effective date of termination.  Full Article

More From Around the Web

BRIEF-Sumitomo Dainippon Pharma completes full acquisition of Cynapsus Therapeutics via unit

* Says its US-based unit completes full acquisition of 100 percent stake of shares and entire warrants in Cynapsus Therapeutics Inc, on Oct. 21 (U.S.A. Eastern Standard Time), at about $635 million